Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ayoko R. Bossou"'
Publikováno v:
British Journal of Cancer
Background: We previously reported that chaetocin has potent and selective anti-myeloma activity attributable to reactive oxygen species (ROS) induction imposed by inhibition of the redox enzyme thioredoxin reductase; we now detail its effects in sol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125873dcc82bd64bde4d087c049d4d05
https://doi.org/10.1038/bjc.2011.522
https://doi.org/10.1038/bjc.2011.522
Autor:
Stefan K.G. Grebe, Crescent R. Isham, Kendall W. Cradic, Ayoko R. Bossou, Keith C. Bible, Dragana Milosevic, Brian C. Netzel
Publikováno v:
The Journal of clinical endocrinology and metabolism. 99(6)
Vascular endothelial growth factor-targeted kinase inhibitors have emerged as highly promising therapies for radioiodine-refractory metastatic differentiated thyroid cancer. Unfortunately, drug resistance uniformly develops, limiting their therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e31f33e1f929519807edbe086690e23
https://pubmed.ncbi.nlm.nih.gov/24628546
https://pubmed.ncbi.nlm.nih.gov/24628546
Autor:
Robert C. Smallridge, Kelly E. Fisher, Eric J. Sherman, Wilma L. Lingle, Laura A. Marlow, Rakesh Kumar, Ayoko R. Bossou, Vera J. Suman, Crescent R. Isham, Vivian Negron, John A. Copland, Keith C. Bible
Publikováno v:
Science Translational Medicine. 5
Anaplastic thyroid cancer (ATC) has perhaps the worst prognosis of any cancer, with a median survival of only about 5 months regardless of stage. Pazopanib monotherapy has promising clinical activity in differentiated thyroid cancers (generally attri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcf56cd437ea493d00962c20bc3d4b33
https://doi.org/10.1126/scitranslmed.3004358
https://doi.org/10.1126/scitranslmed.3004358
Autor:
Wan-Teck Lim, Andrea K. Kukla, Nina J. Karlin, Julian R. Molina, Keith C. Bible, Vera J. Suman, Robert C. Smallridge, Charles Erlichman, Kevin P. Webster, Boon Cher Goh, Anne M. Traynor, Priya Kumar, Jill K. Burton, Pamela Jo Harris, Carolyn Bieber, Michael E. Menefee, Ayoko R. Bossou, William J. Maples, Crescent R. Isham
Publikováno v:
The Journal of clinical endocrinology and metabolism. 97(9)
Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).Preclinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28f9f3eab8ad4ce5eb62ea4875d0b56
https://pubmed.ncbi.nlm.nih.gov/22847238
https://pubmed.ncbi.nlm.nih.gov/22847238
Early B cell factor (EBF) is a transcription factor essential for specification and commitment to the B cell fate. In this study, we show downregulation of a developmentally regulated cluster of hoxa genes, notably hoxa9, coincides with induction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ccb5fec6f5a1ea2157c07a1d5fe6584
https://europepmc.org/articles/PMC3907951/
https://europepmc.org/articles/PMC3907951/
Autor:
Jill K. Burton, Crescent R. Isham, Kevin P. Webster, Ayoko R. Bossou, Pamela Jo Harris, Carolyn Bieber, Charles Erlichman, Priya Kumar, Wan-Teck Lim, VJ Suman, Keith C. Bible, Robert C. Smallridge, William J. Maples, Nina J. Karlin, Julian R. Molina, Anne M. Traynor, Andrea K. Kukla, Boon Cher Goh, Michael E. Menefee
Publikováno v:
Journal of Clinical Oncology. 30:5544-5544
5544 Background: Pazopanib, an orally bioavailable multitargeted inhibitor of kinases including VEGF-R, demonstrated impressive activity in metastatic differentiated thyroid cancer (49% durable RECIST PRs) and promising preclinical activity in anapla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a0aebd0649a1e8a2466c358f587bb74
https://doi.org/10.1200/jco.2012.30.15_suppl.5544
https://doi.org/10.1200/jco.2012.30.15_suppl.5544